IL-17A is targeted by which biologic used in moderate-to-severe psoriasis, and what is the characteristic adverse effect specific to this class (IL-17 inhibitors)?
- A Ustekinumab; paradoxical psoriasis
- B Adalimumab; reactivation of latent tuberculosis
- C Dupilumab; eosinophilia and conjunctivitis
- D Secukinumab/Ixekizumab; increased risk of mucocutaneous Candida infections ✓
Explanation
Secukinumab and ixekizumab are monoclonal antibodies targeting IL-17A; bimekizumab targets both IL-17A and IL-17F. IL-17A plays a critical role in mucosal immunity against Candida; its inhibition specifically increases susceptibility to mucocutaneous candidiasis (oral, vulvovaginal) — the characteristic class-specific adverse effect of IL-17 inhibitors. TB reactivation is a class effect of TNF-alpha inhibitors (adalimumab, infliximab, etanercept). Dupilumab (anti-IL-4Rα, used in atopic dermatitis) causes conjunctivitis. Ustekinumab (anti-IL-12/23) is well-tolerated without the Candida risk.
Reference: Neena Khanna Illustrated Synopsis of Dermatology & STD, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.